Previous investigations indicate that baseline serum IL-6 levels or its changes have been found to be associated with the efficacy of immune checkpoint blockade therapy in NSCLC by altering peripheral T cell population and function (53–55). This evidence concerns the gene IL6 and non-small cell lung carcinoma.